GeNeuro SA
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome (NCT05497089) | GeNeuro SA | 2022-08-29 |
Track GeNeuro SA automatically
Every clearance here is in the API, with alerts when new ones post.